Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma.

被引：6

作者：

Chapman, Paul B.

Ascierto, Paolo Antonio

Schadendorf, Dirk

Grob, Jean Jacques

Ribas, Antoni

Kiecker, Felix

Dutriaux, Caroline

Demidov, Lev V.

Lebbe, Celeste

Rutkowski, Piotr

Blank, Christian U.

Gutzmer, Ralf

Millward, Michael

Kefford, Richard

Huang, Yingjie

Zhang, Ying

Squires, Matthew

Mookerjee, Bijoyesh

Hauschild, Axel

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Ist Nazl Tumori Fdn G Pascale IRCCS, Naples, Italy

[3] Univ Hosp Essen, Essen, Germany

[4] Aix Marseille Univ, Marseille, France

[5] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[6] Charite, Berlin, Germany

[7] CHU Bordeaux, Hop St Andre, Bordeaux, France

[8] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia

[9] Univ Paris Diderot, Paris, France

[10] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[11] Inst Oncol, Warsaw, Poland

[12] Netherlands Canc Inst NKI, Amsterdam, Netherlands

[13] Hannover Med Sch, Hannover, Germany

[14] Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] Westmead Hosp, Sydney, NSW, Australia

[16] Macquarie Univ, Sydney, NSW, Australia

[17] Novartis Pharmaceut, E Hanover, NJ USA

[18] Novartis Pharmaceut AG, Basel, Switzerland

[19] Schleswig Holstein Univ Hosp, Kiel, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9526

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9526

引用

页数：5